J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 22, 2022 for Tau Investment Holdings Pte Ltd & Tau Holdco Pte Ltd J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 22, 2022 for Tau Investment Holdings Pte Ltd & Tau Holdco Pte Ltd J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Updates On Acquisition
Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity Shares on exercise of Stock options pursuant to Employee Stock Option Scheme
J.B. Chemicals acquires Razel from Glenmark
The brand is focused on the cardiac segment in India and Nepal with a total covered market size of 2444 crores, JB Chemicals said J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Disclosure Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Closure of Trading Window
Closure of Trading Window J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - JB Chemicals & Pharmaceuticals Limited (JB Pharma) Receives ANDA Approval For Venlafaxine Hydrochloride Extended-Release Tablets From USFDA.
JB Chemicals & Pharmaceuticals Limited (JB Pharma) receives ANDA approval for Venlafaxine Hydrochloride Extended-Release Tablets from USFDA. J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Enclosed please find Transcript of Conference Call which was scheduled for Investors and Analysts on November 14, 2022 at 3.30 p.m. IST in relation to results and developments for the second quarter ended on September 30, 2022.